• Users Online: 189
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 3  |  Page : 318-325

Role of sodium bicarbonate as adjuvant treatment of nonsevere computed tomography-identified COVID-19 pneumonia: A preliminary report


1 Department of Chest Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 Department of Radiology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt
4 Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

Correspondence Address:
Dr. Rehab Ahmad Elmorsey
Department of Chest Medicine, Faculty of Medicine, Mansoura University, Algamhoria Street, Mansoura 35516
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijrc.ijrc_48_21

Rights and Permissions

Background: Coronaviruses are classified as pH dependent. Alkaline media induced by sodium bicarbonate (SB) could impede viral entry into cells. We aimed to study the possible role of SB as an adjuvant treatment of nonsevere COVID-19 pneumonia. Methods: The study included 182 adults with confirmed nonsevere COVID-19 and chest computed tomography (CT) pneumonia; 127 assigned as study received conventional treatment plus adjuvant SB inhalation and nasal drops, as well as 55 assigned as control treated by conventional treatment only. Clinical and radiological assessments using chest CT score specific for COVID-19 were done at days 0 and 30. Results: Both the groups were comparable regarding demographic, clinical, and radiological characteristics. Clinical recovery was reported in 43/127 (33.9%) and 10/55 (18.2%) of the study and control groups, respectively (P = 0.03). The mean ± standard deviation time to clinical improvement was 3.31 ± 0.99 and 9.79 ± 6.29 days for the study and control groups, respectively (P < 0.001). The median of the total chest CT score was reduced from 10 (4–15) to 3 (0–19) in the study group (P = 0.000) and from 13 (2–15) to 11 (2–19) in the control group (P = 0.53) on days 0 and 30, respectively. Conclusions: SB could be a possible adjuvant therapy for selected patients with nonsevere COVID-19 pneumonia.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed240    
    Printed0    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal